Sex-Specific Drug Response in Chronic Multimorbidity: A Comprehensive Review

Abstract

Sex-specific drug response is a critical, yet often underappreciated, consideration in the management of patients with chronic multimorbidity. Despite increasing recognition of sex-based biological differences, therapeutic strategies frequently overlook the impact of sex on pharmacodynamics and pharmacokinetics, contributing to variations in efficacy, safety, and clinical outcomes. This review synthesizes current evidence on the subject, discussing epidemiological trends, underlying pathophysiological mechanisms, risk factors, clinical presentations, diagnostic challenges, and tailored management strategies. Emphasis is placed on integrating guideline-based and emerging therapeutic approaches that acknowledge sex as a determinant of drug response, offering practical insights for clinicians managing complex multimorbid patients.

Introduction

Chronic multimorbidity, defined as the coexistence of two or more chronic diseases in an individual, presents a formidable challenge in modern clinical practice, especially given the aging global population. The interplay between multiple diseases and their treatments increases the risk of adverse drug reactions, polypharmacy, and suboptimal outcomes. Biological sex is a fundamental determinant of disease pathogenesis, progression, and response to therapy, yet sex-specific considerations remain insufficiently integrated into routine care. Understanding the nuances of sex-based differences in drug response is essential for optimizing outcomes in patients with chronic multimorbidity, reducing iatrogenic harm, and advancing personalized medicine.

Epidemiology / Disease Burden

Chronic multimorbidity affects a significant proportion of the adult population, with prevalence estimates ranging from 30% to 60% in individuals over 65 years. Epidemiological data from recent cohorts suggest that women are more likely to develop multimorbidity at an earlier age and experience a higher burden of associated disability compared to men. Sex differences also exist in the patterns of comorbid disease clusters; for instance, women exhibit higher rates of autoimmune, metabolic, and musculoskeletal disorders, while men more commonly present with cardiovascular and respiratory comorbidities. These disparities influence not only the clinical course but also the response to pharmacological interventions, underscoring the importance of sex-specific approaches.

Pathophysiology

The biological basis for sex-specific drug response in multimorbidity is multifactorial. Genetic, hormonal, and molecular differences contribute to distinct pharmacokinetic and pharmacodynamic profiles. For example, sex hormones modulate the expression and activity of cytochrome P450 enzymes, influencing drug metabolism rates. Females often have greater body fat percentage and lower glomerular filtration rates, affecting volume of distribution and renal clearance. Moreover, immune function exhibits sex dimorphism, impacting the pathogenesis of autoimmune and inflammatory diseases frequently present in multimorbid patients. These factors collectively alter drug efficacy, toxicity profiles, and the risk of drug-drug interactions.

Risk Factors

Risk factors for sex-differentiated drug responses in chronic multimorbidity extend beyond biological determinants. Sociocultural factors, health-seeking behaviors, and healthcare access also play significant roles. Women, for example, are more likely to report symptoms and seek medical care, potentially leading to earlier diagnosis but also increasing exposure to polypharmacy and its attendant risks. In contrast, men may experience delayed diagnoses and undertreatment of certain conditions. Polypharmacy, comorbid organ dysfunction, and age-related physiological changes further exacerbate the risk of adverse drug events, with evidence suggesting that these risks manifest differently across sexes.

Clinical Features

Sex-specific clinical features in chronic multimorbidity are often subtle but clinically impactful. Women with multimorbidity may present with atypical symptoms for common diseases such as coronary artery disease, leading to diagnostic delays and mismanagement. Conversely, men may have more classic presentations but are at higher risk for acute complications. Differences in pain perception, drug side effect profiles, and susceptibility to adverse drug reactions are well-documented. For instance, women are more prone to drug-induced QT prolongation, while men may be at elevated risk for statin-induced myopathy. Recognizing these patterns is essential for individualized care.

Diagnosis

Diagnostic challenges in assessing drug response among multimorbid patients are heightened by sex-specific variations in disease manifestation and biomarker expression. Diagnostic criteria for several chronic conditions were historically derived from predominantly male cohorts, reducing their sensitivity in female patients. Sex differences in laboratory reference ranges, imaging findings, and symptom reporting complicate the diagnostic process, potentially resulting in underdiagnosis or misclassification. Comprehensive assessment tools that incorporate sex-specific thresholds and patient-reported outcomes are increasingly advocated in clinical guidelines to enhance diagnostic accuracy.

Treatment & Management

Optimal management of chronic multimorbidity necessitates a nuanced approach to pharmacotherapy that incorporates sex-specific considerations. Dose adjustments, drug selection, and monitoring protocols should be tailored to account for differences in absorption, distribution, metabolism, and elimination. For example, women may require lower initial doses of certain anticoagulants or psychotropics due to slower metabolism and higher risk of bleeding or central nervous system side effects, respectively. Men may benefit from aggressive lipid-lowering strategies but require vigilance for myopathic complications. Multidisciplinary care models and regular medication reviews are key to minimizing adverse outcomes and improving therapeutic efficacy.

Recent Advances / Emerging Therapies

Recent advances in pharmacogenomics and precision medicine are poised to transform the management of sex-specific drug responses in multimorbidity. Genome-wide association studies have elucidated sex-linked genetic variants influencing drug metabolism enzymes, enabling the development of sex-specific dosing algorithms. Novel therapeutic agents, such as SGLT2 inhibitors and PCSK9 inhibitors, have demonstrated differential benefits and risks in male and female subgroups in cardiovascular outcome trials. Digital health innovations, including electronic decision support systems, now incorporate sex-specific alerts to guide prescribing and monitoring. These developments hold promise for closing the gap in personalized care for multimorbid patients.

Guideline Recommendations

International guidelines are increasingly recognizing the importance of sex-specific considerations in chronic disease management. The American Heart Association, European Society of Cardiology, and other bodies advocate for sex-stratified risk assessment and individualized therapy in multimorbid patients. Recommendations emphasize the need for sex-specific reference values, proactive screening for adverse drug reactions, and increased research participation of women in clinical trials. Clinicians are urged to remain vigilant to sex-based differences throughout the diagnostic and therapeutic continuum, integrating current evidence into shared decision-making with patients.

Conclusion

Sex-specific drug response in chronic multimorbidity is a complex and evolving field that demands ongoing attention from clinicians, researchers, and policymakers. Integrating sex as a critical variable in the assessment, diagnosis, and management of multimorbid patients enhances therapeutic outcomes and patient safety. As the evidence base grows, future clinical practice will increasingly rely on precision approaches that tailor pharmacotherapy to the unique biological and clinical profiles of each patient, ultimately improving quality of life and healthcare delivery for both men and women.